# OnCo record paper-eng-imblaze370-atezolizumab-cobimetinib-colorectal-lancet-oncol-2019 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-eng-imblaze370-atezolizumab-cobimetinib-colorectal-lancet-oncol-2019/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-eng-imblaze370-atezolizumab-cobimetinib-colorectal-lancet-oncol-2019" ;
  schema:name "Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370)"@en ;
  schema:description "The phase 3 test of the idea that a MEK inhibitor could warm up an immunologically cold bowel cancer. It failed: neither immunotherapy alone nor the combination beat an existing pill."@en ;
  schema:url <https://onco.cc/key-papers/paper-eng-imblaze370-atezolizumab-cobimetinib-colorectal-lancet-oncol-2019/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S1470-2045(19)30027-0>, <https://pubmed.ncbi.nlm.nih.gov/31003911/> ;
  schema:sameAs <https://doi.org/10.1016/S1470-2045(19)30027-0> ;
  schema:datePublished "2019"^^xsd:gYear ;
  schema:author "Eng C, Kim TW, Bendell J, et al." ;
  onco:cancers <https://onco.cc/cancers/colorectal/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/pd1/> ;
  onco:drugs <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/regorafenib/> ;
  onco:pathways <https://onco.cc/pathways/pd1-checkpoint/>, <https://onco.cc/pathways/ras-mapk/>, <https://onco.cc/pathways/immune-desert-exclusion/> ;
  onco:terms <https://onco.cc/terms/mss-pmmr/>, <https://onco.cc/terms/cold-vs-hot/> ;
  onco:journals <https://onco.cc/journals/lancet-oncology/> .